Xenetic Biosciences (NASDAQ:XBIO – Get Free Report)‘s stock had its “neutral” rating reissued by research analysts at HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports.
Xenetic Biosciences Trading Up 0.2 %
Xenetic Biosciences stock opened at $4.08 on Tuesday. Xenetic Biosciences has a 1-year low of $2.78 and a 1-year high of $5.97. The firm’s 50 day simple moving average is $3.96 and its 200 day simple moving average is $3.98. The firm has a market capitalization of $6.29 million, a PE ratio of -1.39 and a beta of 2.29.
Xenetic Biosciences (NASDAQ:XBIO – Get Free Report) last issued its earnings results on Tuesday, August 13th. The company reported ($0.83) earnings per share for the quarter, meeting the consensus estimate of ($0.83). Xenetic Biosciences had a negative return on equity of 43.40% and a negative net margin of 182.99%. The company had revenue of $0.73 million during the quarter, compared to analysts’ expectations of $0.54 million. Research analysts forecast that Xenetic Biosciences will post -0.96 earnings per share for the current year.
Xenetic Biosciences Company Profile
Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.
Featured Stories
- Five stocks we like better than Xenetic Biosciences
- The How and Why of Investing in Gold Stocks
- Target Hits the Mark: Q2 Earnings Exceed Expectations
- How to Invest in Blue Chip Stocks
- Is Tesla’s Rebound Just Starting? Why You Should Consider Buying
- Canada Bond Market Holiday: How to Invest and Trade
- Stanley Druckenmiller’s Latest Bet: MELI—Should You Follow Suit?
Receive News & Ratings for Xenetic Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.